Kangfang bio-targeting IL-4R new drug approved clinically in the United States

On December 1, Kangfang Bio announced its independent research and development of the innovative drug AK120, which was approved by the FDA to carry out a phase 1b clinical study for the treatment of moderate to severe atopic dermatitis in the United States. AK120 is a new type of autoimmune disease treatment drug targeting IL-4Rα, which can achieve clinical treatment of allergic autoimmune diseases by inhibiting the biological activity of dual cytokines IL-4 and IL-13. According to the press release, the product is intended to treat allergic diseases such as atopic dermatitis and asthma.

At present, AK120 has completed the safety, tolerability and pharmacokinetics clinical studies of a single subcutaneous injection dose escalation in healthy subjects in New Zealand, and is conducting multiple subcutaneous treatments in New Zealand and Australia for subjects with moderate to severe atopic dermatitis. Phase 1b clinical study of increasing injection dose. Preliminary blind research data show that AK120 injection administered to subjects with moderate to severe atopic dermatitis can take effect quickly, reduce the area of skin lesions, and relieve symptoms such as erythema, induration, and exfoliation of the skin.

Atopic dermatitis is the most common disease in dermatology. Related public data shows that the global incidence of adults and children is as high as 10% and 20%, respectively. According to the press release, the low penetration rate and excellent clinical performance of IL-4R monoclonal antibody are expected to meet the unfinished needs of global patients to a certain extent.

The press release also shows that tens of millions of patients around the world still lack more effective biologic therapy for asthma, chronic obstructive pulmonary disease and other type 2 inflammatory diseases. The advantages of IL-4R monoclonal antibody in terms of efficacy and safety are expected to provide new benefits for patients with related diseases.